SDF2L1 and metabolic dysfunction-associated steatohepatitis: These data suggest that dys-regulation of Sdf2l1 is a missing link between insulin resistance and NAFLD/NASH, and can serve as a therapeutic target for diabetes and NAFLD/NASH.